BioCentury | Nov 3, 2017
Company News

Microbiotix partners with AMR Centre to develop bacterial virulence inhibitor

...develop a bacterial virulence inhibitor candidate targeting drug resistant Gram-negative bacteria including Pseudomonas aeruginosa from Microbiotix's...
...Centre will provide up to $1.1 million in technical support and project funding. In March, Microbiotix...
...clinic. The AMR Centre provided funding to CARB-X (see BioCentury Innovations, Oct. 6, 2016 ). Microbiotix Inc....
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...Therapeutics Inc. announced the close of its series A round this week. Oppilotech Ltd. and Microbiotix Inc....
...for multidrug-resistance infections, including A. baumannii and Enterobacteriaceae $469 million; $4 million Phase I 1998 Microbiotix Inc....
BioCentury | Oct 29, 2015
Product R&D

Qureing antibiotic resistance

...agents. At least three - AstraZeneca plc 's MedImmune LLC unit, KaloBios Pharmaceuticals Inc. and Microbiotix Inc....
...agreement in 2014. KaloBios continues to seek a partner to advance KB001-A for other indications. Microbiotix...
...Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Debiopharm Group, Lausanne, Switzerland MedImmune LLC, Gaithersburg, Md. Microbiotix Inc....
BioCentury | Feb 27, 2014
Distillery Therapeutics

Indication: Infectious disease

...lead molecule. SciBX 7(8); doi:10.1038/scibx.2014.228 Published online Feb. 27, 2014 Patent application filed; licensed to Microbiotix Inc....
BioCentury | Jan 7, 2013
Company News

Microbiotix, Merck deal

...Worcester, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck granted Microbiotix...
BioCentury | Jan 3, 2013
Company News

Merck licenses HCV compounds to Microbiotix

...Merck & Co. Inc. (NYSE:MRK) granted Microbiotix Inc. (Worcester, Mass.) exclusive, worldwide rights to two non-nucleoside HCV...
BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...$1.7 7 ND MacroGenics Inc. $1.7 7 $126.6 Celldex Therapeutics Inc. (NASDAQ:CLDX) $1.7 7 $95.8 Microbiotix Inc....
BioCentury | Jun 30, 2003
Company News

Synta management update

...VP of IP and legal affairs, formerly co-founder, COO and VP of business development for Microbiotix Inc....
BioCentury | Mar 11, 2002
Clinical News

Respiratory syncytial virus regulatory update

...relates to the company's MBX 300 oral compound in preclinical testing to treat RSV infection. Microbiotix Inc....
BioCentury | Feb 25, 2002
Company News

Microbiotix management update

...Group plc's CADx Medical Systems subsidiary; he replaces A. Kirk Field, who becomes chairman of Microbiotix's...
Items per page:
1 - 10 of 22
BioCentury | Nov 3, 2017
Company News

Microbiotix partners with AMR Centre to develop bacterial virulence inhibitor

...develop a bacterial virulence inhibitor candidate targeting drug resistant Gram-negative bacteria including Pseudomonas aeruginosa from Microbiotix's...
...Centre will provide up to $1.1 million in technical support and project funding. In March, Microbiotix...
...clinic. The AMR Centre provided funding to CARB-X (see BioCentury Innovations, Oct. 6, 2016 ). Microbiotix Inc....
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...Therapeutics Inc. announced the close of its series A round this week. Oppilotech Ltd. and Microbiotix Inc....
...for multidrug-resistance infections, including A. baumannii and Enterobacteriaceae $469 million; $4 million Phase I 1998 Microbiotix Inc....
BioCentury | Oct 29, 2015
Product R&D

Qureing antibiotic resistance

...agents. At least three - AstraZeneca plc 's MedImmune LLC unit, KaloBios Pharmaceuticals Inc. and Microbiotix Inc....
...agreement in 2014. KaloBios continues to seek a partner to advance KB001-A for other indications. Microbiotix...
...Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Debiopharm Group, Lausanne, Switzerland MedImmune LLC, Gaithersburg, Md. Microbiotix Inc....
BioCentury | Feb 27, 2014
Distillery Therapeutics

Indication: Infectious disease

...lead molecule. SciBX 7(8); doi:10.1038/scibx.2014.228 Published online Feb. 27, 2014 Patent application filed; licensed to Microbiotix Inc....
BioCentury | Jan 7, 2013
Company News

Microbiotix, Merck deal

...Worcester, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck granted Microbiotix...
BioCentury | Jan 3, 2013
Company News

Merck licenses HCV compounds to Microbiotix

...Merck & Co. Inc. (NYSE:MRK) granted Microbiotix Inc. (Worcester, Mass.) exclusive, worldwide rights to two non-nucleoside HCV...
BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...$1.7 7 ND MacroGenics Inc. $1.7 7 $126.6 Celldex Therapeutics Inc. (NASDAQ:CLDX) $1.7 7 $95.8 Microbiotix Inc....
BioCentury | Jun 30, 2003
Company News

Synta management update

...VP of IP and legal affairs, formerly co-founder, COO and VP of business development for Microbiotix Inc....
BioCentury | Mar 11, 2002
Clinical News

Respiratory syncytial virus regulatory update

...relates to the company's MBX 300 oral compound in preclinical testing to treat RSV infection. Microbiotix Inc....
BioCentury | Feb 25, 2002
Company News

Microbiotix management update

...Group plc's CADx Medical Systems subsidiary; he replaces A. Kirk Field, who becomes chairman of Microbiotix's...
Items per page:
1 - 10 of 22